Newsgather

treatment

Sabit384 haber17 kaynakSon güncelleme: 10 sa önce

Son Haberler

Drugmakers Envision Future of Obesity Treatments Beyond GLP-1s
Gelişiyor
Sağlık·2 g önceAI özeti

Drugmakers Envision Future of Obesity Treatments Beyond GLP-1s

Drugmakers are exploring new obesity treatments beyond GLP-1s, including less frequent shots and pills with fewer side effects. Eli Lilly's experimental drug retatrutide showed significant weight loss, while competitors like Novo Nordisk, Structure Therapeutics, AstraZeneca, Pfizer, and Amgen are developing new oral and injectable options. The market is expected to grow significantly, with pricing and insurance coverage being key factors.

C
CNBC US Markets
Chinese researchers' findings influencing global urological cancer treatment, says expert
Gelişiyor
Sağlık·2 g önceAI özeti

Chinese researchers' findings influencing global urological cancer treatment, says expert

Chinese urological cancer experts are now influencing global treatment models, according to Professor Ye Dingwei. At the 2026 ASCO annual meeting, five studies from China were presented, with Ye's team from Fudan University Shanghai Cancer Center contributing three oral presentations on bladder and prostate cancer. Their research focuses on optimizing perioperative strategies, first-line treatments for advanced cancers, and salvage therapies for drug-resistant cases, marking a shift from surgical platforms to comprehensive treatment and original research.

中国新闻网
Drug diversion schemes more effective than prosecution, study finds
Gelişiyor
Law·2 g önceAI özeti

Drug diversion schemes more effective than prosecution, study finds

A new analysis of over 62,000 criminal incidents in England found that drug diversion schemes, which steer individuals towards treatment and education instead of prosecution, are significantly more effective in reducing reoffending than traditional legal approaches. Despite evidence of their success, these schemes are underutilized, with disparities in their application based on socioeconomic status and race.

G
Guardian UK
Life Biosciences' Experimental Treatment ER-100 Administered to First Patient in Phase 1 Trial
Gelişiyor
Sağlık·2 g önceAI özeti

Life Biosciences' Experimental Treatment ER-100 Administered to First Patient in Phase 1 Trial

Life Biosciences has administered its experimental treatment ER-100, targeting age-related vision loss diseases like glaucoma and NAION, to the first participant in a Phase 1 clinical trial. The treatment aims to restore cellular gene expression patterns to a younger state. The primary focus of this early-stage trial is to assess the safety and tolerability of ER-100 in humans.

H
Hürriyet Teknoloji